← All trials
NCT04460807
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Feb 28, 2023
- First posted
- Jul 8, 2020
- Last posted
- Jul 8, 2020
- Enrollment
- 468
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GenoaLead sponsor
- University of GenoaOverall official - principal investigator
- Mario Negri InstituteCollaborator
- University of GenoaReponsible party - principal investigator
- Universita' Cattolica del Sacro CuoreCollaborator
- Federation of Italian Cooperative Oncology GroupsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.